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Introduction: Studies have proposed that mesenchymal stem cells (MSCs) improve the hematopoietic engraftment
in allogeneic or xenogeneic transplants and this is probably due to the MSCs’ immunosuppressive properties. Our
study aimed to discern, for the first time, whether MSC infusion could facilitate the engraftment of hematopoietic
stem cells (HSCs) in autologous transplantations models, where no immune rejection of donor HSCs is expected.
Methods: Recipient mice (CD45.2) mice, conditioned with moderate doses of radiation (5-7 Gy), were transplanted
with low numbers of HSCs (CD45.1/CD45.2) either as a sole population or co-infused with increasing numbers of
adipose-derived-MSCs (Ad-MSCs). The influence of Ad-MSC infusion on the short-term and long-term engraftment
of donor HSCs was investigated. Additionally, homing assays and studies related with the administration route and
with the Ad-MSC/HSC interaction were conducted.
Results: Our data show that the co-infusion of Ad-MSCs with low numbers of purified HSCs significantly improves
the short-term and long-term hematopoietic reconstitution of recipients conditioned with moderate irradiation
doses. This effect was Ad-MSC dose-dependent and associated with an increased homing of transplanted HSCs in
recipients’ bone marrow. In vivo and in vitro experiments also indicate that the Ad-MSC effects observed in
this autologous transplant model are not due to paracrine effects but rather are related to Ad-MSC and HSC
interactions, allowing us to propose that Ad-MSCs may act as HSC carriers, facilitating the migration and
homing of the HSCs to recipient bone marrow niches.
Conclusion: Our results demonstrate that Ad-MSCs facilitate the engraftment of purified HSCs in an
autologous mouse transplantation model, opening new perspectives in the application of Ad-MSCs in
autologous transplants, including HSC gene therapy.Introduction
Mesenchymal stem cells (MSCs) are fibroblast-like cells
capable of differentiating into different cell lineages [1–3]
and of exerting immunosuppressive properties through
their interaction with the innate and adaptive immune
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extracellular matrix, cytokines, and growth factors, all of
which are essential for hematopoietic stem cell (HSC)
maintenance and differentiation [2, 3].
The unique immunosuppressive properties of MSCs
have led to their clinical application for the treatment of
several inflammatory diseases, mainly graft-versus-host
disease (GVHD) in allogeneic HSC transplants (HSCTs)
[8, 9] but also in autoimmune diseases such as multiple
sclerosis [10, 11] and Crohn’s disease [12, 13] among
others. Additionally, several MSC-based therapies have
been applied in the field of regenerative medicine [14–17].This article is distributed under the terms of the Creative Commons Attribution
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side effects in any of their clinical applications, proving
the safety of their use [18].
In addition to their application in the abovementioned
clinical settings, MSCs have been used to facilitate the en-
graftment of HSCs, both in experimental transplantation
models and in clinical applications. In experimental models,
MSCs improved the engraftment of human CD34+ cells
transplanted into non-obese diabetic/severe combined
immunodeficiency (NOD/SCID) mice [19, 20]. In humans,
MSCs have been used in allogeneic transplants to limit
risks of graft failure [21–23].
The HSC engraftment effect mediated by MSCs in
xeno- or allogeneic transplants might be attributed to the
immunosuppressive properties of the MSCs. However, in
autologous HSC transplants, in which no immune reac-
tion between donor and host tissues is expected, only one
pilot study was performed in patients with advanced
breast cancer, which suggested that MSCs may accelerate
HSC engraftment and platelet recovery after high-
dose chemotherapy and HSC rescue. Although the
feasibility and safety of MSC co-infusion were demon-
strated in this study, the absence of a control group
limited their conclusions [24].
In spite of the studies conducted so far, it is currently
unknown whether MSCs would be able to facilitate the
HSC engraftment in an autologous transplantation con-
text. A more direct effect of MSCs favouring the HSC
engraftment moved us to explore this possibility. We
reasoned that if this was the case, MSCs would have a
significant value in HSC gene therapy applications to
facilitate the engraftment of gene-corrected HSCs.
To achieve this aim, in the current studies, we used a
congenic CD45.1 and CD45.2 mouse transplantation
model, in which mouse adipose-derived MSCs (Ad-MSCs)
were co-transplanted with purified HSCs into recipient
mice. Our data demonstrate, for the first time, the rele-
vance of Ad-MSCs to facilitate the stable engraftment of
HSCs in an autologous transplantation model. Signifi-
cantly, this effect was most evident when limiting engraft-
ment conditions (i.e., low numbers of HSCs and mild
conditioning regimes were used), opening new perspectives
to the use of MSCs in hematopoietic gene therapy.
Methods
Mice
B6D2F1 (H2b/d, CD45.2), P3D2F1 (H2b/d, CD45.1/CD45.2),
mice, aged 10–12 weeks, were housed and bred at the
CIEMAT (Centro de Investigaciones Energéticas, Med-
ioambientales y Tecnológicas) Laboratory Animals Facility
(registration number ES280790000183) from breeding
pairs originally obtained from The Jackson Laboratory
(Bar Harbor, ME, USA). Mice were routinely screened for
pathogens, in accordance with FELASA (Federation ofEuropean Laboratory Animal Science Associations) proce-
dures, and received water (50 m filtered and ultraviolet
irradiated) and food (SAFE R04 25 KGy gamma-
irradiated) ad libitum. All experimental procedures were
carried out in accordance with Spanish and European reg-
ulations (Spanish RD 53/2013 and Law 6/2013 that trans-
poses and fulfill the European Directive 2010/63/UE
about the use and protection of vertebrate mammals used
for experimentation and other scientific purposes). Proce-
dures were approved by the Ethical Committee of Animal
Experimentation of the CIEMAT in accordance with all
external and internal bio-safety and bio-ethics guidelines.
Generation and characterization of mouse Ad-MSCs
Adipose tissue-derived mesenchymal stem cells (Ad-
MSCs) were generated from B6D2F1 mice epiploon
adipose tissue. Fat was cut into pieces, digested for 2
h with 1 mg/ml collagenase A (Roche Diagnostics GmbH,
Mannheim, Germany) in DMEM, centrifuged, and filtered
through 40-μm filters. Samples were then cultured at 37 °C,
5 % CO2 in flasks (Nalge Nunc International, Rochester,
NY, USA) at 1.6×105 cells/cm2, in MesenCult medium plus
supplements for mouse cells (Stemcell Technologies,
Vancouver, BC, Canada). After 24 h, non-adherent cells
were discarded. Fresh medium was added and replaced
twice a week. At 80 % confluence, adherent cells were tryp-
sinized, washed, and seeded at 4×103 cells/cm2. In all the
experiments, Ad-MSCs were used at 5–8 passages.
The osteogenic and adipogenic Ad-MSC differenti-
ation capacity was demonstrated by using StemXVivo™
Osteogenic/Adipogenic Base Media Supplemented with
StemXVivo™ Osteogenic Supplement or StemXVivo™
Adipogenic Supplement (R&D Systems, Minneapolis,
MN, USA), respectively, in accordance with the instruc-
tions of the manufacturer.
For immunophenotype analysis, Ad-MSCs were har-
vested with 0.05 % trypsin-EDTA, washed, resuspended
in 1 % bovine serum albumin (Sigma-Aldrich, St. Louis,
MO, USA) supplemented phosphate-buffered saline
(PBS), incubated 30 m at 4 °C with monoclonal anti-
bodies, and washed. The flow cytometry analysis in-
cluded CD34, CD45.1, CD45.2, CD90, CD117, CD105,
CD73, CD166, and CD29 expression (BD Biosciences
Pharmingen, San Diego, CA, USA). Results were ana-
lyzed with FlowJo Analysis (Tree Star, now part of
FlowJo LLC, Ashland, OR, USA).
Hematopoietic stem cell purification
BM cells were isolated from tibias and femurs of
P3D2F1 mice by flushing DMEM into each bone. Cells
were subjected to red blood cells lysis and resuspended
in PBS. Purified HSCs, LSK (lineage-negative, Sca-1+,
cKit+) cells, were obtained by whole BM cell sorting by
using lineage-specific antibodies (anti-Gr1, anti-B220,
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and anti-cKit antibodies (BD Biosciences). LSK cells
were sorted by using a BD Influx cell sorter (BD Bio-
sciences). After cell sorting, 90.75 ± 5 % LSK cells
purities were obtained.
Hematopoietic stem cell transplants
Donor hematopoietic cells were obtained from P3D2F1
mice (CD45.1/CD45.2), while B6D2F1 (CD45.2) mice
were always used as recipients. In some experiments, BM
cells from primary recipients were re-transplanted into
secondary and tertiary recipients. Twenty-four hours
before hematopoietic transplantation was performed, re-
cipient mice were irradiated with x-ray equipment MG324
(300 kV, 12.8 mA; Philips, Hamburg, Germany).
Donor cell engraftment was analyzed by flow cytome-
try at different times post-transplantation by analyzing
the proportion of CD45.1+ and CD45.2+ cells. Peripheral
blood (PB) or BM cells were stained with anti-CD45.1
and anti-CD45.2 (BioLegend, San Diego, CA, USA)
mouse monoclonal antibodies and analyzed after treat-
ing the cells with red blood cell lysis solution. Results
were analyzed with FlowJo Analysis (Tree Star). All
HSCT experiments were repeated at least three times.
Each study group totaled 10–15 mice.
Bio-distribution assays
LSK cells were stained with DiD (Invitrogen, Waltham,
MA, USA) in accordance with the protocol of the manu-
facturer. Purified 104 LSK cells, with or without 6×105 Ad-
MSCs, were intravenously infused in 5 Gy-irradiated
B6D2F1 recipient mice. Mice were sacrificed 2, 4, and 24 h
after transplant. Lungs, spleen, blood, and BM were ana-
lyzed by flow cytometry to determine the number of DiD+
cells in each organ. For BM, analyses were performed in
cell suspensions generated by tibial and femoral BM. Total
BM was estimated assuming that femoral and tibial BM
correspond to 25 % of total BM [25].
Duplets analysis
Ad-MSCs were detached from culture plates with 0.25 %
Trypsine-EDTA (Gibco, Life Technologies, Carlsbad,
CA, USA) and stained with carboxyfluorescein succinimi-
dyl ester (CFSE) (Molecular Probes, Invitrogen). Similarly,
purified LSK cells were stained with DiD (Molecular
Probes, Invitrogen) in accordance with the protocol of the
manufacturer. Ten minutes after the incubation of stained
cells (6×105 Ad-MSCs and 1500 LSK-DiD+CFSE+), single
cell or duplet cell populations were analyzed by flow
cytometry. This period was established considering the
time in which Ad-MSCs and LSK cells were mixed prior
to infusion in mice.
In some experiments, Ad-MSCs and LSK cells were
analyzed by using the ImageStream100 flow cytometer(Amnis Corporation, Seattle, WA, USA) and images
were collected on a six-channel charge-coupled device
(CCD) digital camera. Each cell image was decomposed
into six separate sub-images, each corresponding to a
different color component.
Statistical analysis
Statistical analysis was performed by one-way analysis of
variance on rank with Tukey post hoc test. Results are
expressed as mean ± standard error of the mean and
were considered significant if the P value was not more
than 0.05. Statistical analysis was performed with the
GraphPad Prism 5.00 for Windows (GraphPad Software,
Inc., La Jolla, CA, USA).
Results
Ad-MSCs enhance the engraftment of purified HSCs in
congenic recipients conditioned with non-myeloablative
radiation
In the current studies, MSCs obtained from adipose tissue
(Ad-MSCs) were used throughout. Consistent with our
previous studies, Ad-MSCs showed the characteristic
fibroblast-like morphology (Fig. 1a), had osteogenic and
adipogenic differentiation capacity (Fig. 1b, c), and were
negative for hematopoietic marker expression and positive
for CD29, CD44, CD73, CD90.2, CD105, CD106, CD144,
and CD166 expression (Fig. 1d).
To investigate the impact of Ad-MSCs on HSC engraft-
ment, sub-lethally irradiated recipient mice (CD45.2/
CD45.2) were transplanted with 1500 purified LSK cells
from congenic (CD45.1/CD45.2) mice, either with or
without Ad-MSCs (106 Ad-MSCs per mouse) (Fig. 2a).
In a first set of experiments, recipient mice were irra-
diated with a relatively high dose of 7 Gy. As shown in
Fig. 2b, high levels of donor hematopoietic engraftment
were observed in all instances, and no differences of en-
graftment could be found between mice infused with or
without Ad-MSCs.
In a second set of experiments, recipient mice were
conditioned with a lower radiation dose of 5 Gy. Under
these radiation conditions, the co-infusion of Ad-MSCs
with the LSK markedly increased the engraftment of the
LSK cells (Fig. 2c). As shown in the figure, differences
remained significant and stable throughout the 12-week
post-transplantation period of analysis. These results
show that Ad-MSCs improve the engraftment of purified
LSK cells, particularly in recipients subjected to mild
conditioning.
The hematopoietic engraftment-supportive effect of Ad-
MSCs is dose-dependent
To investigate whether the engraftment effect of Ad-MSCs
was dose-dependent, 1500 LSK cells were co-infused with
increasing numbers of Ad-MSCs (from 2×105 Ad-MSCs to
Fig. 1 Mouse Ad-MSC characterization. a Ad-MSCs’ fibroblast-like morphology. b Osteogenic differentiation. c Adipogenic differentiation. d Ad-MSC
immunophenotype, negative for hematopoietic markers CD34, CD45.1, CD80, and low Sca-1 and positive for CD29, CD44, CD73, CD90.2, CD105,
CD106, CD144, and CD166 expression. Ad-MSC adipose tissue-derived mesenchymal stem cell
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Analyses performed 4 weeks after transplant showed
that the co-infusion of 2×105 Ad-MSCs did not in-
crease the engraftment of LSK cells, as compared
with data obtained when the LSK cells were trans-
planted as a sole population. In contrast to this data,
the co-infusion of 4×105 Ad-MSCs mediated a signifi-
cant increase in the engraftment of LSK cells, an ob-
servation that was even more marked when 6×105
Ad-MSCs/mouse were co-infused. No further incre-
ments were observed in the group co-infused with
106 Ad-MSCs (Fig. 3a). When analyses were per-
formed at 8 and 12 weeks after transplant, doses of
6×105 and 106 Ad-MSCs still showed improvements
in the engraftment of purified LSK cells (see fold in-
creases of engraftment in Fig. 3a and representative
absolute values of engraftment in Fig. 3b). These results
thus demonstrate that the hematopoietic engraftmenteffect of Ad-MSCs is dose-dependent. Additionally, our
data indicate that relatively low doses of Ad-MSCs can ac-
celerate the engraftment of transplanted LSK cells but that
higher Ad-MSC doses are required to improve LSK cell
engraftment in later stages post-transplantation.Ad-MSCs improve the engraftment of long-term
hematopoietic repopulating cells
In subsequent experiments, we investigated whether the
engraftment effect of Ad-MSCs was applicable not only
to short-term repopulating progenitor cells but also to
true HSCs. As in our previous experiments, in these
studies 5 Gy-irradiated recipients were transplanted with
1500 LSK cells, either with or without 6×105 Ad-MSCs.
Six months after transplantation, BM cells from each of
the two recipient groups were pooled and then re-
transplanted into secondary recipients that had been
Fig. 2 Influence of Ad-MSC co-infusion on HSC engraftment in congenic recipients conditioned with non-myeloablative irradiation. a CD45.2+
recipient mice were transplanted with 1500 purified donor CD45.1+/CD45.2+ LSK cells, with or without 106 Ad-MSCs co-infusion. Donor cell
engraftment in peripheral blood of recipients conditioned with b 7 Gy or c 5 Gy. Bars represent standard error of the mean. **P ≤ 0.01.
Ad-MSC adipose tissue-derived mesenchymal stem cell, HSC hematopoietic stem cell, HSCT hematopoietic stem cell transplant, LSK lineage−
Sca-1+ cKit+, ns non-significant difference
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stitution. Three months later, BM cells from secondary
recipients were further transplanted into tertiary recipi-
ents also conditioned with 11 Gy.
As observed in previous experiments (Fig. 3), a dose
of 6×105 Ad-MSCs significantly increased LSK en-
graftment in primary recipients during the first weeks
after transplant, although at 12 and 24 weeks post-
transplantation differences did not reach statistical
significance (Fig. 4a). This figure also shows that most
of the PB analyses performed in secondary and ter-
tiary recipients revealed improved donor engraftments
in the LSK + Ad-MSC group, as compared with the
LSK group. Consistent with these observations, the
proportion of precursor cells that were of donor ori-
gin (percentage of LSK cells that were CD45.1
+/CD45.2+) in pooled BM samples that were trans-
planted in secondary and tertiary recipients was also
higher in the LSK + Ad-MSC groups (Fig. 4b, c).These experiments allow us to conclude that the co-
infusion of Ad-MSCs improves the engraftment not
only of progenitors responsible for the early stages of
hematopoietic engraftment but also of long-term re-
populating HSCs.Ad-MSCs improve the homing of transplanted LSK cells
into the BM of recipient mice
To elucidate whether the increased engraftment of LSK
cells associated with Ad-MSC co-infusion was due to
an improved homing of transplanted LSK cells into re-
cipient BM, 104 LSK cells stained with a vital dye (DiD)
were transplanted, either with or without 6×105 Ad-
MSCs/mouse, into 5 Gy-irradiated recipients. At 2, 4,
and 24 h after infusion, the percentage of the trans-
planted DiD+ LSK cells present in femoral BM, and by
extrapolation in the whole BM, as well as in PB, spleen,
and lung, was determined.
Fig. 3 Ad-MSC dose-dependent effect on HSC engraftment transplanted into congenic recipients conditioned with moderate radiation.
a Fold-increase of donor hematopoietic engraftment in peripheral blood of 5 Gy-irradiated recipient mice transplanted with 1500 LSK cells co-infused
with increasing numbers of Ad-MSCs. b Evolution of peripheral blood donor engraftment in the peripheral blood of recipient mice co-infused with
1500 LSK plus 6×105 or 106 Ad-MSCs. Data obtained at 4, 8, and 12 weeks post-transplantation are shown. Bars represent standard error of the mean.
*P ≤ 0.05. ***P ≤ 0.001. Ad-MSC adipose tissue-derived mesenchymal stem cell, HSC hematopoietic stem cell, HSCT hematopoietic stem cell transplant,
LSK lineage− Sca-1+ cKit+, ns non-significant difference
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the homing of LSK cells in recipients’ BM at all investi-
gated time points (2, 4, and 24 h) (Fig. 5a). Neither in PB
(Fig. 5b) nor in the spleen (Fig. 5c) did Ad-MSC co-
infusion modify the presence of LSK cells in these
tissues. However, at 24 h post-transplantation, in-
creased numbers of donor LSK cells were observed in
the lung of recipients that had been transplanted with
Ad-MSCs (Fig. 5d), indicating that the increased
homing of LSK cells in BM was not due to a de-
creased trapping of these cells in the lung.
These results strongly suggest that the improved en-
graftment of LSK cells associated with Ad-MSC co-
infusion, and thus the accelerated and sustained
hematopoietic reconstitution of transplanted recipients,
is mediated by the improved homing of transplanted
precursor cells and HSCs in recipient BM.Ad-MSC-HSC co-infusion is essential for the supportive
hematopoietic engraftment effect of Ad-MSCs
To investigate whether the HSC engraftment effects
mediated by Ad-MSCs require their co-infusion with the
LSK cells, two different sets of experiments were con-
ducted. In the first experiments (Fig. 6), a group of re-
cipient mice was co-infused with 1500 purified LSK cells
together with Ad-MSCs, as in our previous experiments.
Additional groups of transplanted mice were now in-
cluded, in which the total Ad-MSC dose was split into
up to three infusions that were administered either the
day before or both the day before and the day after the
co-infusion of LSK and Ad-MSCs (see experimental
protocol in Fig. 6a). As shown in Fig. 6b, doses of 6×105
and 106 Ad-MSCs—which markedly improved the
engraftment of 1500 LSK cells when co-infused in a
single dose—had no effect when divided into three
Fig. 4 Short-term and long-term hematopoietic engraftment of recipient mice co-infused with purified HSCs and Ad-MSCs. a Donor CD45.1+/CD45.2+
cell engraftment detected in CD45.2+ recipients’ peripheral blood. Five gray-irradiated primary recipients were infused 1500 LSK, with (gray bars) or
without (white bars) 6×105 Ad-MSC co-infusion. Secondary and tertiary recipients were irradiated with 11 Gy and transplanted with pooled 2×106 BM
cells obtained 24 weeks after HSCT from the primary recipients and at 12 weeks after HSCT from the secondary recipients. b Flow cytometry analysis
showing the percentage of LSK cells that were of donor CD45.1+/CD45.2+ origin in pooled BM samples from primary recipients (CD45.2+) 24 weeks
after transplantation. c Similar analyses conducted in pooled BM samples from secondary recipients (CD45.2+) 12 weeks after transplantation. Bars
represent standard error of the mean. *P ≤ 0.05. **P ≤ 0.01. ***P ≤ 0.001. Ad-MSC adipose tissue-derived mesenchymal stem cell, BM bone marrow,
HSC hematopoietic stem cell, HSCT hematopoietic stem cell transplant, LSK lineage− Sca-1+ cKit+, ns non-significant difference
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the LSK cells. These studies thus indicate that the total
effective dose of Ad-MSCs need to be infused with the
LSK cells at the moment of the LSK infusion but not
earlier or later than LSK infusion.
In subsequent experiments represented in Fig. 7, the
beneficial engraftment effect of Ad-MSCs was investi-
gated in recipients in which Ad-MSCs (106 cells) were
IV co-infused with the LSK cells, with respect to recipi-
ents in which the Ad-MSCs were infused via intraperito-
neal (IP) injection simultaneously to the IV injection of
LSK cells. In previous studies, we demonstrated that ananti-GVHD effect of IV-injected Ad-MSCs is reproduced
by IP-administered Ad-MSCs if the cell dose was two-
fold increased [26]. In our current experiments, doses of
106 or 2×106 Ad-MSCs were, therefore, considered.
In contrast with data obtained in mice IV co-infused
with LSK and Ad-MSCs, the IP injection of Ad-MSCs
did not mediate any significant effect upon the engraft-
ment of IV infused LSK cells (Fig. 7). These experiments
strongly suggest that the supportive hematopoietic en-
graftment effect of Ad-MSCs is not paracrine but rather
is due to the direct contact between the LSK cells and
the Ad-MSCs.
Fig. 5 Effect of Ad-MSC co-infusion in the homing of transplanted HSCs in the recipients’ organs. Two, four, and 24 hours after the infusion of
DiD+ LSK cells, the number present in a bone marrow, b peripheral blood, c spleen, and d lungs of recipient mice was determined. The figure represents
the proportion of the infused DiD+ LSK cells detected in each organ. White bars, mice infused with LSK cells. Grey bars, mice co-infused with LSK cells and
Ad-MSCs. Bars represent standard error of the mean. *P ≤ 0.05. Ad-MSC adipose tissue-derived mesenchymal stem cell, HSC hematopoietic stem cell, LSK
lineage− Sca-1+ cKit+, ns non-significant difference
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that after a short incubation (10 minutes) of DiD+ LSK
cells with CSFE+ Ad-MSCs, 83.69 ± 2 % of the LSK cells
formed DiD+/CFSE+ cell duplets, showing the close
interaction between both cell types (Fig. 8a, b). In similar
experiments, co-incubated PE+ LSK and fluorescein
isothiocyanate-positive (FITC+) Ad-MSCs were analyzed
by image stream flow cytometry methods to examine the
direct interaction of the two cell populations. In Fig. 8c,
the intimate association of LSK and Ad-MSCs is shown.These final observations suggest that Ad-MSCs may act
as LSK carriers in vivo, thus facilitating the migration
and homing of the HSC and hematopoietic progenitor
cells into the BM niche during the early stages after
transplantation.
Discussion
Previous studies have shown that MSCs have important
immunosuppressive properties [27–29] and are constitu-
tive of the BM microenvironment, where they secrete
Fig. 6 Influence of Ad-MSC dose fractionation on the engraftment of purified HSCs. a Illustration of the experimental protocol corresponding to
results shown in b. As a control group, 5 Gy-irradiated mice were intravenously infused with 1500 LSK cells on day 0. Three study groups received
one to three different Ad-MSC doses intravenously co-infused, following different administration schemes, depicted in the figure’s experimental
design. b Analysis of the donor cell engraftment (fold-increase) with respect to mice transplanted with 1500 LSK cells. Bars represent standard
error of the mean. *P ≤ 0.05. ***P ≤ 0.001. Ad-MSC adipose tissue-derived mesenchymal stem cell, HSC hematopoietic stem cell, LSK lineage−
Sca-1+ cKit+, ns non-significant difference
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studies have demonstrated a beneficial MSC effect on
HSC engraftment in xenogeneic transplants in NOD/
SCID mice [19, 20]. In humans, MSCs have been used
to improve or accelerate (or both) the hematopoietic en-
graftment in different allogeneic HSCT settings with risk
of engraftment failure [21, 23, 31]. In these case reports,
the proposed hematopoietic engraftment effects of
MSCs are commonly associated with the immunosup-
pressive effects of MSCs, which may limit the immune
reactions between host and donor cells. However, the
question of whether other, non-immunological effects
could play a role in the hematopoietic engraftment effect
mediated by MSCs has never been investigated, even in
the context of autologous transplantation.We have, therefore, investigated the hematopoietic en-
graftment effect of Ad-MSCs by using an autologous
hematopoietic transplantation model based on the infu-
sion of donor CD45.1+/CD45.2+ LSK cells into congenic
CD45.2 recipient mice. In this study, Ad-MSCs were used
throughout since these cells are more easily obtained in
large quantities than BM-MSCs and share similar pheno-
typic and functional characteristics [28, 32, 33].
Our first experiments showed that the co-infusion of
Ad-MSCs did not have any impact on the engraftment
of purified LSK cells if these cells are transplanted into
recipients conditioned with a relatively high dose of 7
Gy, a radiation dose associated with high levels of
engraftment because of the very high mortality of the
recipient’s endogenous hematopoiesis. In contrast with
Fig. 7 Influence of Ad-MSC administration route on the engraftment of purified HSCs. Donor cell engraftment (fold increase) in the peripheral
blood of recipient mice intravenously infused with 1500 LSK cells (white bars), with intravenous co-infusion of 106 Ad-MSCs (gray bars), or with
intraperitoneal injection of 106 (striped bars) or 2×106 (dark gray bars) Ad-MSCs. Bars represent standard error of the mean. ***P ≤ 0.001. Ad-MSC
adipose tissue-derived mesenchymal stem cell, HSC hematopoietic stem cell, IP intraperitoneal injection, IV intravenous infusion, LSK lineage−
Sca-1+ cKit+, ns non-significant difference
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ducted in recipients conditioned with a lower dose of 5
Gy, a significant increase in the engraftment of purified
LSK cells was induced by Ad-MSCs.
Consistent with previous observations in NOD/SCID
mice transplanted with human CD34+ cells [20], an evi-
dent Ad-MSC dose-dependent hematopoietic engraftment
effect was observed in our autologous transplantation
model. This increase was more significant during the first
few weeks after HSCT, a period which is particularly crit-
ical after transplantation. In subsequent experiments
based on the serial BM transplantations, we demonstrate
that Ad-MSCs improve the engraftment not only of the
short-term repopulating cells but also of the true HSCs.
One of the possible mechanisms underlying the
supporting engraftment effect of Ad-MSCs could be
related to the numerous cytokines and growth factors
secreted by these cells, which may increase the prolif-
eration of engrafted hematopoietic precursors. Alter-
natively, Ad-MSCs could improve the homing of
transplanted HSCs in the BM niches. This hypothesis
was confirmed by our experiments represented in
Fig. 5, which demonstrate that Ad-MSCs increase the
homing of transplanted LSK cells in recipients’ BM
during the early stages post-infusion.
To elucidate whether paracrine-mediated Ad-MSC
effects could account for the improved engraftments ob-
served in transplanted recipients, Ad-MSCs administration
was either fractioned in up to three different consecutive
infusions or injected via IP, instead of intravenously co-in-
fused with the LSK cells. None of these Ad-MSC adminis-
tration approaches facilitated the engraftment of purified
LSK cells. This contrasts our earlier studies [26], in whichthe IP administration of Ad-MSCs was able to control
GVHD in mice transplanted with allogeneic cells, indicat-
ing that soluble factors released by the Ad-MSCs are key
immune-suppressors of the GVHD. In our current studies,
the IV co-infusion of Ad-MSC/LSK was mandatory to me-
diate a significant hematopoietic engraftment effect. These
results, together with the observation that after only 10 min
of LSK and Ad-MSC incubation most of LSK cells co-
localize with Ad-MSCs, strongly suggest that the LSK/Ad-
MSCs interaction is a requisite to improve the engraftment
of transplanted HSCs.
Whether or not other sources of MSCs share the
hematopoietic engraftment ability now described for
Ad-MSCs is currently unknown. However, observations
showing similar phenotypic and functional properties
in MSCs obtained from different sources [32] would
suggest that the effects reported in our study may not
be specific for Ad-MSCs.
The results obtained in this study would have a
practical application in the field of HSC gene therapy,
particularly for the treatment of diseases, such as
Fanconi anemia, in which the collection of clinically
relevant numbers of HSCs constitutes one of the bot-
tlenecks to restore patient hematopoiesis with autolo-
gous gene-corrected HSCs [34, 35]. Improving the
engraftment of autologous HSCs by MSC co-infusion
would have further advantages in several other gene
therapy applications in which corrected HSCs do not
develop a proliferation advantage over uncorrected
HSCs [36–39]. Moreover, the observation that the
HSC engraftment effect of MSCs is most significant
when moderate conditioning is used further suggests
that MSC co-infusion would help to minimize toxic
Fig. 8 Flow cytometry analysis of the rapid in vitro interaction of HSCs with Ad-MSCs. a Representative flow cytometry duplet analysis of 6×105
CFSE-stained Ad-MSCs and 1500 DiD-stained LSK cells, 10 minutes after co-culture. b Percentage of DiD+LSK cells forming duplets with CFSE+
Ad-MSCs detected in the different assays. c Multi-spectral images of PE+ LSK cells and FITC+ Ad-MSCs. Individual cells and three representative
duplets are shown by a row of images that include side scatter signal (blue), FITC signal (green), PE signal (orange), and FITC and PE signals
together (merged column). Bright-field (BF) of each cell sample is also represented. Ad-MSC adipose tissue-derived mesenchymal stem cell, CFSE
carboxyfluorescein succinimidyl ester, DAPI 4',6-diamidino-2-phenylindole, FITC fluorescein isothiocyanate, FSC forward scatter, HSC hematopoietic
stem cell, LSK lineage− Sca-1+ cKit+, PE phycoerythrin, SSC side scatter
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gene therapy protocols [36–39].
Conclusions
Taken together, our data demonstrate for the first time
in an autologous mouse transplantation model that Ad-MSCs improve the homing of donor hematopoietic stem
and progenitor cells into recipient BM niches, facilitating
the stable reconstitution of transplanted recipients with
infused hematopoietic grafts. The conclusions of this
study would have a practical application in the field of
HSC transplants, including gene therapy.
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